Biogen

Current directors and officers who also hold a role at another S&P 500 company.

• Jesus B. MantasIFF · Director
• Maria C. FreireARE · Director
• Monish D. PatolawalaADM · CFO

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Mar 11, 2026

   On March 11, 2026, Biogen Inc. (the “Company”) announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026. The Company has initiated a search to identify the Company’s next Chief Legal Officer.

   Read the 8-K filing
2. Feb 11, 2026

   On February 11, 2026, Caroline Dorsa, Chair of the Biogen Inc. (“Biogen” or the “Company”) Board of Directors (the “Board”) announced that she would not stand for re-election to the Board at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Ms. Dorsa’s decision to not stand for reelection was not related to any disagreement with the Board or the Company on any matter relating to its operations, policies or practices.

   Read the 8-K filing
3. Jan 15, 2025

   On January 13, 2025, Biogen Inc. (the “Company”) appointed Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller and designated Mr. Godbout as the Company’s principal accounting officer, in each case effective as of March 1, 2025. In connection with Mr. Godbout’s appointment as Chief Accounting Officer, Robin Kramer, the Company’s current Chief Accounting Officer, will no longer be designated as the Company’s principal accounting officer as of the effective date of Mr. Godbout’s appointment. As previously announced, Ms. Kramer has been appointed the Company’s Chief Financial Officer, effective upon the retirement of Michael McDonnell, the Company’s current Chief Financial Officer. Mr. McDonnell will retire on March 1, 2025. Mr. Godbout, age 50, joined the Company in 2007 and has served as Global Corporate Controller since October 2023.

   Read the 8-K filing
4. Oct 30, 2024

   On October 28, 2024, Michael McDonnell, Chief Financial Officer of Biogen Inc. (the “Company”) notified the Company that he will retire from the Company effective February 28, 2025. Robin Kramer, the Company’s Chief Accounting Officer and Head of Global Business Services and Treasury has been appointed Chief Financial Officer effective upon Mr. McDonnell’s retirement. In the coming weeks and months, Mr. McDonnell will work closely with Ms. Kramer to ensure a smooth transition. Ms. Kramer, age 59, joined the Company in 2018 and has served as our Senior Vice President, Chief Accounting Officer since December 2020. Prior to that, Ms. Kramer served as our Vice President, Chief Accounting Officer from November 2018 to December 2020. In this capacity, she has overseen key finance functions and led the Company’s Global Business Services and Treasury departments. Before joining the Company, Ms.

   Read the 8-K filing
5. Sep 12, 2024

   (d) Appointment of Dr. Lloyd Minor and Prof Sir Menelas Pangalos to the Board of Directors On September 11, 2024, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) increased the size of the Board and elected Lloyd B. Minor, M.D. and Sir Menelas (Mene) Pangalos, Ph.D. as directors, effective October 1, 2024 and January 1, 2025, respectively, with each director’s term expiring at the Company’s 2025 Annual Meeting of Stockholders. Dr. Minor and Prof Sir Pangalos will receive the annual cash and equity compensation received by each of the Company’s non-employee directors, as described in the Company’s proxy statement dated as of April 26, 2024. Both Dr.

   Read the 8-K filing
6. Nov 8, 2023

   On November 6, 2023, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) elected Monish Patolawala as a director (term to expire at the 2024 Annual Meeting) to fill a vacancy, effective January 1, 2024. Mr. Patolawala qualifies as an “audit committee financial expert” within the meaning of applicable Securities Exchange Commission regulations and may be appointed by the Board of Directors (“Board) to the Board’s Audit Committee. Mr. Patolawala and the Company will enter into an indemnification agreement on the same terms as the Company has previously entered into with its other directors, a form of which has been previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2011. 2

   Read the 8-K filing
7. Mar 9, 2023

   On March 5, 2023, Stelios Papadopoulos, Chair of the Biogen Inc. (“Biogen” or the “Company”) Board of Directors (the “Board”) announced that he would not stand for re-election to the Board at the 2023 Annual Meeting of Stockholders (the “Annual Meeting”). Dr. Papadopoulos’ decision to not stand for reelection was not related to any disagreement with the Board or the Company on any matter relating to its operations, policies or practices.

   Read the 8-K filing
8. Nov 10, 2022

   On November 10, 2022, Biogen Inc. (“Biogen”) announced that the Board of Directors (the “Board”) has completed its search for a new Chief Executive Officer (“CEO”) and has appointed Christopher A. Viehbacher, age 62, to serve as President and CEO of Biogen, beginning November 14, 2022. As previously announced by Biogen, in connection with the appointment of Mr. Viehbacher, Michel Vounatsos will step down as Biogen’s CEO and will resign from the Board. Mr. Viehbacher will succeed Michel Vounatsos as director of Biogen effective November 14, 2022 until Biogen’s next annual meeting of stockholders. Mr. Vounatsos will remain an employee for a limited period of time to assist with the transition. Mr. Viehbacher co-founded Gurnet Point Capital in 2015, where he spent over 7 years, most recently serving as Managing Partner. Prior to joining Gurnet Point Capital, Mr.

   Read the 8-K filing
9. Jun 21, 2022

   On June 21, 2022, Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization announced that he has accepted a new role outside of Biogen, Inc. (the “Company”). His last day at the Company will be June 30, 2022.

   Read the 8-K filing
10. May 3, 2022

    On May 3, 2022, Biogen Inc. (the "Company") announced that it had begun a search for a new Chief Executive Officer ("CEO"). The Company has agreed with its current CEO, Michel Vounatsos, that he will continue to serve as CEO during the interim period, receiving the same compensation and benefits, as well as pro-rated vesting of equity awards, for the period he is CEO. Mr. Vounatsos will remain on the Board of Directors of Biogen until he steps down from his CEO position.

    Read the 8-K filing
11. Jan 31, 2022

    On January 25, 2022, Brian S. Posner notified Biogen Inc. (the “Company” or “Biogen”) that he will retire from the Biogen Board of Directors (the “Board”) effective as of the Company’s 2022 annual meeting of stockholders. Pursuant to the retirement provisions set forth in the Company’s Corporate Governance Principles, Nancy L. Leaming will also retire from the Board effective as of the Company’s 2022 annual meeting of stockholders. Mr. Posner’s and Ms. Leaming’s retirement from the Board are not related to any disagreement with the Board or the Company on any matter relating to its operations, policies, or practices. On January 31, 2022, the Company issued a press release announcing the retirements of Mr. Posner and Ms. Leaming from the Board, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

    Read the 8-K filing
12. Nov 17, 2021

    On November 15, 2021, Biogen Inc. (the “Company”) issued a press release announcing that Alfred W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company, effective December 31, 2021. A copy of the Company’s press release is being furnished as Exhibit 99.1 and is incorporated herein by reference.

    Read the 8-K filing
13. Apr 9, 2021

    On April 7, 2021, Robert W. Pangia notified Biogen Inc. (the “Company” or “Biogen”) that he will retire from the Board of Directors (the “Board”) and will not stand for reelection at the Company's 2021 annual meeting of stockholders. Mr. Pangia will remain a director of the Company until the Company’s 2021 annual meeting of stockholders, scheduled for June 2, 2021. Mr. Pangia’s decision to not stand for reelection was not related to any disagreement with the Company on any matter relating to its operations, policies or practices. On April 9, 2021, the Company issued a press release announcing the retirement of Mr. Pangia, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

    Read the 8-K filing
14. Sep 21, 2020

    On August 15, 2020, Jeffrey D. Capello ceased to be the Executive Vice President and Chief Financial Officer of Biogen Inc. (the “Company”) and ceased to be employed by the Company effective September 15, 2020. In connection with Mr. Capello’s departure, he will receive the severance benefits required under the Company’s executive severance policy for Executive Vice Presidents. In addition, in recognition of Mr. Capello’s contributions to the Company, the Compensation and Management Development Committee of the Board of Directors waived the requirement that Mr. Capello be required to repay 35% of his original cash sign-on bonus and approved a cash payment to him of $2.6 million.

    Read the 8-K filing
15. Jul 22, 2020

    On July 21, 2020, Biogen Inc. (the “Company”) announced the appointment, effective as of August 15, 2020, of Michael R. McDonnell as Executive Vice President and Chief Financial Officer of the Company. Jeffrey D. Capello will step down as Executive Vice President and Chief Finance Officer of the Company effective upon Mr. McDonnell’s appointment on August 15, 2020, and will remain with the Company until September 15, 2020, to assist with the transition. Mr. McDonnell, age 56, has served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, from December 2015 until July 2020. Prior to that, Mr.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.